Other News To Note.

o Aastrom Biosciences Inc., of Ann Arbor, Mich., said its wholly owned subsidiary, Zellera AG, entered an agreement with Mathys Medical Ltd., of Bettlach, Switzerland, to begin a trial using Aastrom's Tissue Repair Cells with Mathys' commercial synthetic bone graft matrix for bone graft applications. The trial, which is expected to accrue five to 10 patients with serious tibia fractures, will be conducted at the Bergmannsheil University Clinic in Bochum, Germany.

o Acacia Research Corp., of Newport Beach, Calif., said CombiMatrix designed and fabricated a microarray based on the SARS (severe acute respiratory syndrome) coronavirus genome published earlier this week. Acacia, which said the first microarrays were fabricated within 48 hours of publication of the genome, said the technology would help confirm the link between the coronavirus and SARS as well as assist in the development of screening tests for the virus and medicines to treat the syndrome.

o Achillion Pharmaceuticals Inc., of New Haven, Conn., and Phytobiotech Inc., of Laval, Quebec, entered a collaboration to discover drugs that address infectious disease targets. Phytobiotech will supply Achillion with purified, plant-derived small molecules called phytochemicals, which Achillion will screen through its infectious disease target assays. The companies will jointly develop any resulting drug candidates. Financial terms were not disclosed.

o Aclara BioSciences Inc., of Mountain View, Calif., entered a partnership to identify and characterize clinical biomarkers for cancer with the University of Southern California's Norris Comprehensive Cancer Center and Hospital in Los Angeles. Initially, they will apply Aclara's multiplexed eTag Assay System to discover breast cancer biomarkers, which could be used to correlate disease type and progression and eventually improve treatment. Financial terms were not disclosed.

o Applied Genetics Inc. Dermatics, of Freeport, N.Y., said it regained all rights to T4N5 Liposome Lotion in connection with the termination of the Dimericine Development Corp. …

Log in to your account to read this article – and millions more.